LABIANA HEALTH S.A.EO-10 (F:8RK) — Market Cap & Net Worth
Market Cap & Net Worth: LABIANA HEALTH S.A.EO-10 (8RK)
LABIANA HEALTH S.A.EO-10 (F:8RK) has a market capitalization of $40.60 Million (€34.73 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #22624 globally and #1992 in its home market, demonstrating a 28.95% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LABIANA HEALTH S.A.EO-10's stock price €7.35 by its total outstanding shares 8489255 (8.49 Million). Analyse LABIANA HEALTH S.A.EO-10 cash flow conversion to see how efficiently the company converts income to cash.
LABIANA HEALTH S.A.EO-10 Market Cap History: 2022 to 2026
LABIANA HEALTH S.A.EO-10's market capitalization history from 2022 to 2026. Data shows growth from $30.17 Million to $72.95 Million (34.53% CAGR).
LABIANA HEALTH S.A.EO-10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LABIANA HEALTH S.A.EO-10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.40x
LABIANA HEALTH S.A.EO-10's market cap is 0.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
105.73x
LABIANA HEALTH S.A.EO-10's market cap is 105.73 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $30.17 Million | $57.85 Million | -$8.94 Million | 0.52x | N/A |
| 2023 | $11.71 Million | $58.46 Million | -$4.42 Million | 0.20x | N/A |
| 2024 | $26.80 Million | $66.26 Million | $253.45K | 0.40x | 105.73x |
Competitor Companies of 8RK by Market Capitalization
Companies near LABIANA HEALTH S.A.EO-10 in the global market cap rankings as of May 5, 2026.
Key companies related to LABIANA HEALTH S.A.EO-10 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #497 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #524 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #531 globally with a market cap of $49.66 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #571 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #497 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #524 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #531 | Zoetis Inc | NYSE:ZTS | $49.66 Billion | $112.68 |
| #571 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $41.87 |
LABIANA HEALTH S.A.EO-10 Historical Marketcap From 2022 to 2026
Between 2022 and today, LABIANA HEALTH S.A.EO-10's market cap moved from $30.17 Million to $ 72.95 Million, with a yearly change of 34.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €72.95 Million | +67.81% |
| 2025 | €43.47 Million | +62.22% |
| 2024 | €26.80 Million | +128.81% |
| 2023 | €11.71 Million | -61.18% |
| 2022 | €30.17 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of LABIANA HEALTH S.A.EO-10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.60 Million USD |
| MoneyControl | $40.60 Million USD |
| MarketWatch | $40.60 Million USD |
| marketcap.company | $40.60 Million USD |
| Reuters | $40.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms,… Read more